CHIN - CIHR Human Immunology Network. Research in Human Immunology Clinical Care and Public Policy in Canada
You are using a browser that is not standards-compliant (possibly Netscape 4). The information on this Web site will be accessible to you, but for a list of Web browsers that comply with the World Wide Web Consortium standards, please visit our Web standards page.
CHIN Nodes...

University of British Columbia

 

 

Node Leader
University of British Columbia
Dr. Rusung Tan

The Immunity in Health and Disease (IHD) research program headed by
Dr. Tan
is based at the Child & Family Research Institute (CFRI), a UBC affiliated research institute adjacent to B.C. Children’s Hospital (BCCH).

BCCH is a tertiary/quaternary care pediatric facility serving a population of over 4 million individuals throughout BC and Yukon, and research within the IHD program is highly translational, driven by and building upon clinical problems that exist within patients in the adjacent hospital. The IHD program is home to UBC’s FOCIS Centre of Excellence in Clinical Immunology and has extensive collaborations throughout North America. Investigators at CFRI are supported by a broad range of technical cores for sequencing, bioinformatics, proteomics, imaging and advanced flow cytometry core. It also has a Tetramer Core for synthesis of a variety of HLA class I tetramers, a unique facility in Canada. The node has a Level 3 Pathogen Facility that can accommodate studies of M. tuberculosis and B. cepacia in human disease, and a clinical Research and Evaluation Unit for clinical study and monitoring visits of patients. The node has patient/Tissue Registries and Biobanking Facility with particular strengths in type 1 diabetes patients and tonsil specimens.

IHD is home to over twenty principal investigators, working at one site, with a primary focus on primary immunodeficiencies, type 1 diabetes, inflammatory bowel diseases, maternal pre- eclampsia, and vaccines. Members have an extensive clinical research within the Vaccine Evaluation Centre (with Phase 2/3/4 clinical trials) and the Division of Pediatric Rheumatology (juvenile inflammatory arthritides, pediatric SLE).